NCT05273749: A trial that was reported late by Tonix Pharmaceuticals, Inc.
This trial has reported, although it was 12 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT05273749 |
|---|---|
| Title | A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of TNX-102 SL Taken Daily At Bedtime In Patients With Fibromyalgia |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | April 6, 2022 |
| Completion date | Nov. 14, 2023 |
| Required reporting date | Nov. 13, 2024, midnight |
| Actual reporting date | Nov. 26, 2024 |
| Date last checked at ClinicalTrials.gov | Dec. 5, 2025 |
| Days late | 12 |